| Similar Articles |
|---|
 |
The Motley Fool
January 26, 2005
Charly Travers |
Protein Design Muscles Up Biotech company buys itself a bigger future. The company announced that it had acquired privately held ESP Pharma for $300 million cash and $175 million stock.   |
The Motley Fool
May 3, 2005
Charly Travers |
PDL's Well-Stocked Pipeline A broad drug portfolio makes this biotech, Protein Design Labs, a long-term winner. |
The Motley Fool
December 13, 2004
Charly Travers |
PDL Rakes It In A robust revenue stream combined with an exciting drug pipeline is this biotech's recipe for success. |
The Motley Fool
March 15, 2005
Charly Travers |
PDL Eyeing Up Profits A timely acquisition is paying off for this drug maker. Investors, take note. |
The Motley Fool
August 5, 2005
Charly Travers |
No Surprise Over PDL's Upside Protein Design Labs' overwhelmingly positive earnings release is good news for shareholders. |
The Motley Fool
January 12, 2005
Charly Travers |
Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise. |
The Motley Fool
August 29, 2007
Brian Lawler |
PDL Lands in a Hazard The biopharma announces a dramatic shift following the failure of its lead drug. Shares of PDL are down only 19% this morning, presumably because the thought of a leaner and thriftier PDL with its royalty-generating potential is a welcome relief to some investors. |
The Motley Fool
July 9, 2004
Charly Travers |
Protein Design Labs' Windfall Royalties from Genentech could mean big things for PDL. |
The Motley Fool
August 4, 2004
Charly Travers |
Labs' Report Offers Mixed Results TProtein Design Labs' royalty intake looks great, but its drug development does not. |
The Motley Fool
February 25, 2005
Charly Travers |
Protein Design Labs' Future A look ahead to a transitional year -- and how much the ESP Pharma acquisition will boost revenues -- coming Monday. |
The Motley Fool
July 14, 2005
Charly Travers |
Dueling Fools: Protein Design Labs Bull Rebuttal This biotech's tomorrow is coming today. The company is a clear buy at its current market cap near $2 billion. |
The Motley Fool
February 27, 2007
Brian Lawler |
PDL Keeps Us Waiting PDL BioPharma announces its year-end financial results. Investors, take note. |
The Motley Fool
April 28, 2011
Brian Orelli |
Buying Royalty Streams on the Cheap If management can't do it, PDL Biopharma's investors are in trouble. The trick is to find patents that are secure and a royalty stream that's predictable. |
The Motley Fool
April 14, 2008
Brian Lawler |
PDL BioPharma's Split Decision PDL BioPharma is finally taking further steps to try to realize better value for the different parts of its business. |
The Motley Fool
July 14, 2005
Stephen D. Simpson |
Dueling Fools: Protein Design Labs Bear Protein Design Labs could be a big winner, or a major loser. The biotech has a strong business, but today's stock price isn't "great." |
The Motley Fool
November 2, 2004
Charly Travers |
Just the Medicine for PDL Losses are shrinking as drug royalties spur strong revenue growth. |
The Motley Fool
February 6, 2008
Brian Lawler |
PDL BioPharma Regroups, Piece by Piece The company still brings in plenty of money, despite selling off assets. Investors, take note. |
The Motley Fool
August 2, 2007
Brian Lawler |
PDL Minds Its Mild Manners The biopharma announces placid second-quarter results -- investors, take note. |
The Motley Fool
March 23, 2004
David Nierengarten |
Genentech's Star Power How much higher can Genentech go? |
The Motley Fool
May 21, 2004
Charly Travers |
Protein Design Labs' Mixed Results Protein Design Labs' Nuvion looks like a winner, while other drugs stumble. Nuvion is in early clinical development for the treatment of severe ulcerative colitis and so far the results seem particularly compelling. |
BusinessWeek
May 9, 2005
Catherine Arnst |
Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents. |
The Motley Fool
July 12, 2010
Ryan McBride |
Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009. |
The Motley Fool
December 20, 2007
Brian Orelli |
2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
May 10, 2005
Charly Travers |
The Future of Cancer Therapy Biotech firm Exelixis is blazing a trail for long-term success. Should investors take notice? |
Chemistry World
March 15, 2011
Sarah Houlton |
Benlysta breaks 50 year Lupus drug drought The first new treatment for lupus erythematosus in half a century has been approved by the US Food and Drug Administration |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
January 8, 2010
Brian Orelli |
Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands. |
BusinessWeek
October 6, 2003
Arlene Weintraub |
Drug Development, Genentech Style Its promising colon cancer fighter Avastin is a prime example of how the biotech "keeps following the science." |
The Motley Fool
August 3, 2005
Charly Travers |
Biotech's Big Deal The market is pleased with the partnership between Protein Design Labs and Biogen IDEC. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
The Motley Fool
March 15, 2005
Charly Travers |
The Best Company I've Never Owned The history of Genentech's Avastin, which just completed another phase 3 clinical trial showing that Avastin is effective in the treatment of non-small cell lung cancer. The author laments missing the opportunity to invest. |
The Motley Fool
April 27, 2011
Brian Orelli |
Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
October 1, 2008
Brian Orelli |
3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
March 22, 2005
Travers & Djuranovic |
Stock Madness 2005: Protein Design Labs vs. Taser One keeps you healthy; the other keeps you safe. But which one will make your portfolio happier? "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness shows the way. |
The Motley Fool
January 21, 2010
Brian Orelli |
Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really? |
The Motley Fool
April 27, 2007
Brian Lawler |
PDL Gets the Go-Ahead Signal The biopharma moves its lead compound into phase 3 testing. Investors, take note. |
The Motley Fool
September 3, 2004
Charly Travers |
MGI Pharma's Shopping Spree The company is filling out its drug pipeline with acquisitions. |
The Motley Fool
June 6, 2011
Brian Orelli |
Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market. |
The Motley Fool
November 12, 2007
Brian Lawler |
What's New at PDL BioPharma? The past few volatile months are reflected in the third-quarter results from PDL BioPharma. The future, however, may be smoother. Investors, take note. |
The Motley Fool
March 5, 2008
Brian Lawler |
PDL Taken Off the Block Yesterday, PDL BioPharma announced that it had failed to find an acquirer; instead, it will launch another round of restructuring. |
The Motley Fool
April 21, 2011
Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. |
The Motley Fool
June 30, 2010
Brian Orelli |
Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth? |
The Motley Fool
March 28, 2005
Charly Travers |
Stock Madness 2005: Protein Design Labs vs. Yahoo! Two very different Rule Breakers face off in "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness. |
The Motley Fool
March 11, 2010
Jim Mueller |
Is Medivation a Buy? What is the thinking with regards to Medivation today? It already got a big haircut last week. Is it worth investing in at these lower prices? |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
December 30, 2004
Paul Elliott |
Why Daddy Loves This Stock Investing a friend's hard-earned money can be every bit as unnerving as investing your own. Let's take a look at Protein Design Labs, the leader in antibody humanization technology. |
The Motley Fool
April 29, 2005
Tim Hanson |
Genentech's Promising Future Cancer drug Avastin is finding new uses. How will outside forces affect its potential? Investors take note. |
